ArticleClinical rheumatology2014
Two Takayasu arteritis patients successfully treated with rituximab.
Article in Clinical rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Advancements in medical and surgical treatments of Takayasu arteritis-induced renal arteritis: a systematic review.Chinese medical journal · 2020Pooled it
- Difficult-to-treat Takayasu arteritis: a case-based review.Rheumatology international · 2024Review
- A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis.International journal of molecular sciences · 2024Review
- Elevated serum immunoglobulin level predicts high risk of 1-year recurrence in patients with Takayasu arteritis.Arthritis research & therapy · 2023Article
- A 16-year-old girl with sudden heart failure and nephrotic syndrome associated with Takayasu's arteritis.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Article
- Novel Therapies in Takayasu Arteritis.Frontiers in medicine · 2021Review
- Refractory Takayasu arteritis successfully treated with rituximab: case-based review.Rheumatology international · 2019Review
- [Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica : Safety and efficacy analysis of a nationwide German registry (GRAID2)].Zeitschrift fur Rheumatologie · 2018Article
- Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant.BMJ case reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Takayasu arteritis (TA) is a rare form of chronic large vessel vasculitis of unknown origin involving the aorta and its major branches. Recently, the involvement of B lymphocytes in TA has been suggested, and active refractory TA patients were successfully treated with B cell depletion therapy (BCDT). We report two cases of patients with TA successfully treated with anti-CD20 monoclonal antibody (rituximab). The favorable outcome of rituximab treatment in our patients also support the view that BCDT can be a useful option for refractory TA, and its potential should be evaluated in controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.